Badger C, Buckner C D, Thomas E D, Clift R A, Sanders J E, Stewart P S, Storb R, Sullivan K M, Shulman H, Flournoy N
Leuk Res. 1982;6(3):383-7. doi: 10.1016/0145-2126(82)90101-1.
The results of allogeneic marrow transplantation in 75 patients with acute lymphoblastic leukemia and 63 patients with acute non-lymphoblastic leukemia in relapse are reviewed. The effects of various chemotherapeutic regimens added to the basic regimen of cyclophosphamide (Cy) 60 mg/kg given on each of two successive days followed by 1000 rad of total body irradiation (TBI) were evaluated. The regimens tested were dimethylbusulphan (DMB), 1,3-bis(2-chlorethyl)-1-nitrosourea (BCNU) and daunorubicin. Seventeen of 138 patients are alive between three and nine and a half years from transplantation. The addition of other chemotherapeutic agents to th basic Cy and TBI regimen did not decrease relapse frequency or prolong survival.
回顾了75例急性淋巴细胞白血病患者和63例复发的急性非淋巴细胞白血病患者进行同种异体骨髓移植的结果。评估了在连续两天每天给予60mg/kg环磷酰胺（Cy）的基础方案后，再进行1000拉德全身照射（TBI）的基础上，添加各种化疗方案的效果。所测试的方案为二甲磺酸丁酯（DMB）、1,3-双（2-氯乙基）-1-亚硝基脲（BCNU）和柔红霉素。138例患者中有17例在移植后3至9年半存活。在基础的Cy和TBI方案中添加其他化疗药物并没有降低复发频率或延长生存期。
